Episodes (Page 27)
✨
Pairing software with drugs for optimized dosing.
Hakim Yadi
✨
Administering state EPR programs discussed.
John Hite
✨
Strategies for big pharma to acquire blockbuster drugs.
✨
The lifecycle of a blockbuster drug and indications.
✨
Albert Swane shares strategies for growing consumer health brands.
Albert Swane
✨
Implications of the advancing BIOSECURE Act and potential industry shifts.
✨
Overview of the neoadjuvant therapy landscape in melanoma.
✨
Discussion on the US BIOSECURE Act and its markup vote.
Derrick Gingery
✨
AstraZeneca's Vaxzevria discontinuation and cardiometabolic therapies.
✨
Mark Brown discusses digital trust in the context of cybersecurity.
Mark Brown
✨
Ono acquires US oncology firm; Lilly shows strong growth but faces supply issues.
✨
Tony Perrotta discusses challenges replacing plastic pill packs with sustainable alternatives.
Tony Perrotta
✨
FDA advisory committee reform efforts and potential near-term changes are discussed.
✨
Philips CEO discusses AI framework; BD CTO on R&D initiatives.
Framework; Apple Watch
✨
Datamonitor CNS analysts discuss coverage from the AAN conference.
✨
Top-selling drugs of 2023 and the impact of the COVID cliff are analyzed.
✨
The episode covers the 2024 Global Generics & Biosimilars Awards.
✨
Molecular technology enhances patient safety in CAR-T clinical trials.
✨
Chinese pharma data presented at AACR.
Andrew McConaghie
Brian Yang
Dexter Yan
✨
FDA biosimilar promotion guidance and interchangeability designation impact are analyzed.